Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • SUDA Pharmaceuticals (ASX:SUD) has appointed biochemistry expert Dr Michael Baker as its new CEO
  • Dr Michael has experience in drug development, portfolio management, product testing, and research
  • With a PhD in Biochemistry from La Trobe University, he has helped write over 15 research articles and been cited over 1000 times
  • SUDA creates medical mouth-sprays designed to treat epilepsy, insomnia, and even cancer
  • SUDA’s shares are up 4.29 per cent today currently worth 7.3 cents each

SUDA Pharmaceuticals has appointed biochemistry expert Dr Michael Baker as its new CEO.

Dr Michael will start his new role at the company on January 2, 2020, and with him comes years of experiences both in business and medicine.

As an Investment Associate at Bioscience Managers, Dr Michael has experience in sourcing and landing deals from various events and institutes. He also has experience in portfolio management and the development and testing of different products.

In medicine, Dr Michael has helped write over 15 research articles and accumulated more than 1000 citations.

He spent roughly three years as a Project Manager at biotech company Hexima where he helped guide a peptide drug product through discovery to clinical trials. This involved leading a team of research scientists.

Dr Michael has a PhD in Biochemistry from La Trobe University in Melbourne, as well as a Master of Business Administration from Melbourne Business School.

On top of the new role of CEO, Dr Michael will also be replacing Paul Hopper as Executive Chairman of SUDA, who will become a Non-Executive Chairman.

Paul spoke highly of the calibre of the new company CEO.

“Michael’s expertise across commercialisation of technologies, scientific research and financial investments is a core asset, which is important for SUDA as it repositions itself,” Paul said.

“With refreshed company management going forward we are striving to rebuild company value and shareholder confidence,” he said.

SUDA is focussed on developing drugs in the form of an oral spray. The company says less than 25 per cent of conventional tablet and pill medication is actually absorbed by the body, and so SUDA’s focus is the efficacy of drug delivery.

The company has developed mouth-spray products to treat epilepsy, insomnia, motion sickness, and even cancer.

SUDA’s shares are up 4.29 per cent after today’s news, currently worth 7.3 cents each and trading in a $10.38 million market cap.

SUD by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.